Ferring Pharmaceuticals Moves to Strengthen Growth with Appointment of Chief Medical and Chief Scientific Officers

SAINT PREX, Switzerland--(BUSINESS WIRE)--Ferring Pharmaceuticals announced today the appointment of Pascal Danglas, MD as Executive Vice President and Chief Medical Officer and Per Falk, MD, PhD as Executive Vice President and Chief Scientific Officer. Both appointments are effective as of February 1st.

"Ferring aims to expand its portfolio and improve patient access to our products"
"Ferring aims to expand its portfolio and improve patient access to our products," said Michel Pettigrew, President of the Executive Board and Chief Operating Officer of Ferring. "By focusing our efforts in R&D and patient access under these two proven leaders, Ferring is positioning itself to accelerate growth and better meet patient needs."

As Chief Medical Officer, Pascal Danglas will evaluate and advise on new product candidates. He will also focus on strengthening patient access to Ferring products as the company's liaison to the medical community, patients and national reimbursement authorities. An industry veteran, Danglas previously served as executive vice president of clinical and product development with Ferring.

Per Falk joins Ferring as Chief Scientific Officer after a successful assignment as senior vice president responsible for biopharmaceuticals research at Novo Nordisk A/S. In his new role, Falk will be responsible for overseeing the entirety of Ferring's research and development activities, from basic research through to regulatory approval.

- Ends -

About Ferring Pharmaceuticals:

Headquartered in Saint-Prex, Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. To learn more about Ferring or its products please visit www.ferring.com.

Contacts

Ferring Pharmaceuticals
Helen Gallagher
Tel. +41 (0) 58 301 00 51
[email protected]
or
Patrick Gorman
Tel. +41 (0) 58 301 00 53
[email protected]
 

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.